$DRUG News

Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Bright Minds Biosciences to Present at Upcoming Conferences

What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?

Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145

Bright Minds Biosciences to Present at Upcoming Conferences

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials